Research programme: anticancer therapeutic vaccine - Vedantra Precision Immunity

Drug Profile

Research programme: anticancer therapeutic vaccine - Vedantra Precision Immunity

Alternative Names: ALK-ICMVs; E6-ICMVs; E7-ICMVs

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Vedantra Precision Immunity
  • Class Immunotherapies; Vaccines
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top